Teva®, a division of Deckers Brands (NYSE: DECK), announces the arrival of its spring-summer 2025 collection and new anthem ...

Corcept's new drug, relacorilant, shows promise with positive Phase 3 results and an FDA decision expected. Learn more about ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, ...

The shoe brand has launched "For Playground Earth," a new anthem and collection created to "push people to play outside." ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version ...

Teva Pharmaceutical Industries Ltd. failed to convince the Federal Circuit to reconsider a December ruling that five patents ...

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

A bipartisan Senate bill dubbed the “Skinny Label, Big Savings Act” was introduced in January. The bill would expand the scope of protection ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $200.0 for Deckers Outdoor, spanning the last three ...